SCHEMBL14375586

SCHEMBL14375586

CCCC(C(N)=O)[C@@H](CC(C)C)C(=O)N[C@H]1CCCCN(Cc2cccc(-c3cccc(F)c3)c2)C1=O

nearest known ligand 0.83

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PSEN1 P49768 2/20 0.83
▸ PSEN2 P49810 2/20 0.83
▸ APH1B Q8WW43 2/20 0.83
▸ NCSTN Q92542 2/20 0.83
▸ APH1A Q96BI3 2/20 0.83
▸ PSENEN Q9NZ42 2/20 0.83
▸ APP P05067 15/20 0.75
▸ MMP1 P03956 3/20 0.63
▸ MMP2 P08253 1/20 0.63
▸ MMP7 P09237 1/20 0.63
▸ MMP10 P09238 1/20 0.63
▸ MMP9 P14780 1/20 0.63
▸ MMP13 P45452 1/20 0.63
▸ MMP14 P50281 1/20 0.63
▸ ADAM17 P78536 1/20 0.63
▸ MMP3 P08254 2/20 0.51
▸ NPY1R P25929 1/20 0.45
▸ SRC P12931 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13934114 1.00 PSEN1 (0.83) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL4490561 1.00 PSEN1 (0.83) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL4493875 0.92 APP (0.77) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL13934738 0.92 APP (0.77) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL13934571 0.91 PSEN1 (0.80) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL4490564 0.91 PSEN1 (0.80) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL4479733 0.91 PSEN1 (1.00) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL13934742 0.91 PSEN1 (1.00) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL13934043 0.90 APP (0.82) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL4474533 0.90 APP (0.82) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7304056-B2 Succinoylamino lactams as inhibitors of Aβ protein production BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2007-12-04 — — US disclosed
Send feedback